Asset Details
Do you wish to reserve the book?
ACAN Gene Mutations in Short Children Born SGA and Response to Growth Hormone Treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ACAN Gene Mutations in Short Children Born SGA and Response to Growth Hormone Treatment
Do you wish to request the book?
ACAN Gene Mutations in Short Children Born SGA and Response to Growth Hormone Treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ACAN Gene Mutations in Short Children Born SGA and Response to Growth Hormone Treatment
2017
Overview
Background:Some children born small for gestational age (SGA) show advanced bone age (BA) maturation during growth hormone (GH) treatment. ACAN gene mutations have been described in children with short stature and advanced BA.Objective:To determine the presence of ACAN gene mutations in short SGA children with advanced BA and assess the response to GH treatment.Methods:BA assessment in 290 GH-treated SGA children. ACAN sequencing in 29 children with advanced BA ≥0.5 years compared with calendar age.Results:Four of 29 SGA children with advanced BA had an ACAN gene mutation (13.8%). Mutations were related to additional characteristics: midface hypoplasia (P = 0.003), joint problems (P = 0.010), and broad great toes (P = 0.003). Children with one or fewer additional characteristic had no mutation. Of children with two additional characteristics, 50% had a mutation. Of children with three additional characteristics, 100% had a mutation. All GH-treated children with a mutation received gonadotropin-releasing hormone analog (GnRHa) treatment for 2 years from onset of puberty. At adult height, one girl was 5 cm taller than her mother and one boy was 8 cm taller than his father with the same ACAN gene mutation.Conclusion:This study expands the differential diagnosis of genetic variants in children born SGA and proposes a clinical scoring system for identifying subjects most likely to have an ACAN gene mutation. ACAN sequencing should be considered in children born SGA with persistent short stature, advanced BA, and midface hypoplasia, joint problems, or broad great toes. Our findings suggest that children with an ACAN gene mutation benefit from GH treatment with 2 years of GnRHa.ACAN gene sequencing should be considered in SGA children with persistent short stature, advanced BA, midface hypoplasia, joint problems, or broad great toes. GH treatment with 2 years of GnRHa is beneficial.
Publisher
Endocrine Society,Oxford University Press
Subject
/ Bone Diseases, Developmental - genetics
/ Child
/ Children
/ Female
/ Gonadotropin-releasing hormone
/ Gonadotropin-Releasing Hormone - analogs & derivatives
/ Gonadotropin-Releasing Hormone - therapeutic use
/ Growth Disorders - drug therapy
/ Humans
/ Infant, Small for Gestational Age
/ Male
/ Mutation
/ Puberty
